QuantuMDx Group
QuantuMDx manufactures molecular diagnostic platforms and assays for infectious diseases, delivering rapid multiplex PCR testing at the point of care. Its Q-POC platform is a portable, rapid PCR diagnostic system that delivers results in approximately 30-35 minutes, with CE-IVD marking and sophisticated software algorithms that remove complicated result interpretation. The growing assay portfolio includes tests for…
Funding snapshot
About
QuantuMDx manufactures molecular diagnostic platforms and assays for infectious diseases, delivering rapid multiplex PCR testing at the point of care. Its Q-POC platform is a portable, rapid PCR diagnostic system that delivers results in approximately 30-35 minutes, with CE-IVD marking and sophisticated software algorithms that remove complicated result interpretation. The growing assay portfolio includes tests for SARS-CoV-2, Flu A/B and RSV respiratory panels, sexually transmitted infections, and antimicrobial resistance markers. The platform supports laboratory information system connectivity for seamless test record management. QuantuMDx has established distribution partnerships with Menarini for UK and France and Sansure Biotech for China and and Southeast Asia, and has been included on Public Health England's Microbiology Framework. The company has received the Outstanding Achievement Award at the Medilink Healthcare Business Awards and and Special Recognition at the Med-Tech Innovation Awards. Founded in 2008 and headquartered in Newcastle Upon Tyne, United Kingdom, the company has raised approximately $57.3M in Series D funding from investors including Adjuvo, British Business Bank, 3B Future Health Fund, and WG Partners.
Business model
Infectious Diseases > In Vitro Diagnostic Tests > Diversified > Point Of Care,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Amplification-based > PCR > RT-PCR
Team background
College Wise > Harvard University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.